WO2004050683A8 - Antibodies directed to tumor necrosis factor and uses thereof - Google Patents

Antibodies directed to tumor necrosis factor and uses thereof

Info

Publication number
WO2004050683A8
WO2004050683A8 PCT/US2003/038281 US0338281W WO2004050683A8 WO 2004050683 A8 WO2004050683 A8 WO 2004050683A8 US 0338281 W US0338281 W US 0338281W WO 2004050683 A8 WO2004050683 A8 WO 2004050683A8
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies directed
necrosis factor
tumor necrosis
light chain
immunoglobulin molecules
Prior art date
Application number
PCT/US2003/038281
Other languages
French (fr)
Other versions
WO2004050683A2 (en
WO2004050683A3 (en
Inventor
John S Babcook
Jaspal S Kang
Orit Foord
Larry Green
Xiao Feng
Scott Klakamp
Mary Haak-Frendscho
Palaniswami Rathanaswami
Craig Pigott
Meina L Liang
Rozanne Lee
Kathy Manchulencho
Raffaella Faggioni
Giorgio Senaldi
Qiaojuan Jane Su
Original Assignee
Abgenix Inc
John S Babcook
Jaspal S Kang
Orit Foord
Larry Green
Xiao Feng
Scott Klakamp
Mary Haak-Frendscho
Palaniswami Rathanaswami
Craig Pigott
Meina L Liang
Rozanne Lee
Kathy Manchulencho
Raffaella Faggioni
Giorgio Senaldi
Qiaojuan Jane Su
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abgenix Inc, John S Babcook, Jaspal S Kang, Orit Foord, Larry Green, Xiao Feng, Scott Klakamp, Mary Haak-Frendscho, Palaniswami Rathanaswami, Craig Pigott, Meina L Liang, Rozanne Lee, Kathy Manchulencho, Raffaella Faggioni, Giorgio Senaldi, Qiaojuan Jane Su filed Critical Abgenix Inc
Priority to MXPA05005921A priority Critical patent/MXPA05005921A/en
Priority to CA2508375A priority patent/CA2508375C/en
Priority to JP2004557489A priority patent/JP4754219B2/en
Priority to AU2003298816A priority patent/AU2003298816C1/en
Priority to EP03796574A priority patent/EP1578799B8/en
Priority to DE60333228T priority patent/DE60333228D1/en
Priority to AT03796574T priority patent/ATE472556T1/en
Publication of WO2004050683A2 publication Critical patent/WO2004050683A2/en
Publication of WO2004050683A3 publication Critical patent/WO2004050683A3/en
Publication of WO2004050683A8 publication Critical patent/WO2004050683A8/en
Priority to HK06103052.3A priority patent/HK1083023A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Antibodies directed to the antigen TNFa and uses of such antibodies. In particular, fully human monoclonal antibodies directed to the antigen TNFa. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.
PCT/US2003/038281 2002-12-02 2003-12-02 Antibodies directed to tumor necrosis factor and uses thereof WO2004050683A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
MXPA05005921A MXPA05005921A (en) 2002-12-02 2003-12-02 Antibodies directed to tumor necrosis factor and uses thereof.
CA2508375A CA2508375C (en) 2002-12-02 2003-12-02 Antibodies directed to tumor necrosis factor and uses thereof
JP2004557489A JP4754219B2 (en) 2002-12-02 2003-12-02 Antibodies directed against tumor necrosis factor and their use
AU2003298816A AU2003298816C1 (en) 2002-12-02 2003-12-02 Antibodies directed to Tumor Necrosis Factor and uses thereof
EP03796574A EP1578799B8 (en) 2002-12-02 2003-12-02 Antibodies directed to tumor necrosis factor and uses thereof
DE60333228T DE60333228D1 (en) 2002-12-02 2003-12-02 AGAINST THE TUMOR NEKROSE FACTOR TARGETED ANTIBODIES AND THEIR USES
AT03796574T ATE472556T1 (en) 2002-12-02 2003-12-02 ANTIBODIES DIRECTED AGAINST THE TUMOR NECROSIS FACTOR AND THEIR USES
HK06103052.3A HK1083023A1 (en) 2002-12-02 2006-03-09 Antibodies directed to tumor necrosis factor and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43072902P 2002-12-02 2002-12-02
US60/430,729 2002-12-02

Publications (3)

Publication Number Publication Date
WO2004050683A2 WO2004050683A2 (en) 2004-06-17
WO2004050683A3 WO2004050683A3 (en) 2005-04-14
WO2004050683A8 true WO2004050683A8 (en) 2005-07-28

Family

ID=32469516

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/038281 WO2004050683A2 (en) 2002-12-02 2003-12-02 Antibodies directed to tumor necrosis factor and uses thereof

Country Status (13)

Country Link
US (2) US7285269B2 (en)
EP (1) EP1578799B8 (en)
JP (1) JP4754219B2 (en)
CN (1) CN100434440C (en)
AT (1) ATE472556T1 (en)
AU (1) AU2003298816C1 (en)
CA (1) CA2508375C (en)
DE (1) DE60333228D1 (en)
ES (1) ES2347239T3 (en)
HK (1) HK1083023A1 (en)
MX (1) MXPA05005921A (en)
RU (1) RU2377253C2 (en)
WO (1) WO2004050683A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943342B2 (en) 2004-06-17 2011-05-17 Wyeth Llc Nucleic acids encoding IL-13 binding agents
US8221752B2 (en) 2004-06-09 2012-07-17 Wyeth Llc Antibodies against human interleukin-13 and uses therefor

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US20050249735A1 (en) * 2000-08-07 2005-11-10 Centocor, Inc. Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
EP2371861B1 (en) 2002-01-25 2017-08-09 Novo Nordisk A/S Monoclonal antibodies against extracellular loops of C5aR
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
EP1578799B8 (en) * 2002-12-02 2011-03-23 Amgen Fremont Inc. Antibodies directed to tumor necrosis factor and uses thereof
EP3037105B1 (en) * 2003-06-27 2021-03-17 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
EP1647596A4 (en) * 2003-07-18 2008-02-13 Mochida Pharm Co Ltd Monoclonal antibody against platelet membrane glycoprotein vi
FR2859725B1 (en) * 2003-09-16 2006-03-10 Neovacs HIGH EFFICIENCY PROCESS FOR OBTAINING HUMAN ANTIBODIES THAT NEUTRALIZE THE BIOLOGICAL ACTIVITY OF A HUMAN CYTOKINE
WO2005047328A2 (en) * 2003-11-07 2005-05-26 Curagen Corporation Antibodies against secretoryleukocyte protease inhibitor
AU2004317819A1 (en) * 2003-11-12 2005-10-13 Patrys, Limited Methods of identifying neoplasm-specific antibodies and uses thereof
PT2857418T (en) * 2004-02-06 2017-10-20 Univ Massachusetts Antibodies against clostridium difficile toxins and uses thereof
CA2572098C (en) * 2004-06-30 2015-01-27 Mayo Foundation For Medical Education And Research B7-dc binding antibody
US7501119B2 (en) 2004-06-30 2009-03-10 Mayo Foundation For Medical Education And Research Methods and molecules for modulating an immune response
US20060099203A1 (en) 2004-11-05 2006-05-11 Pease Larry R B7-DC binding antibody
GB0425972D0 (en) * 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
EP1819731A4 (en) * 2004-12-08 2013-02-13 Immunomedics Inc Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
KR101298383B1 (en) * 2005-01-24 2013-08-20 엘란 파마 인터내셔널 리미티드 Specific binding members for ngf
DOP2006000093A (en) * 2005-04-25 2007-01-31 Pfizer ANTIBODIES AGAINST MYOSTATIN
HUE025608T2 (en) * 2005-09-07 2016-03-29 Amgen Fremont Inc Human monoclonal antibodies to activin receptor-like kinase-1 (ALK-1)
CN1954882A (en) * 2005-10-14 2007-05-02 李海 Use of long active human recombination solubility tumor necrosin alpha receptor in preparation of medicine for treating hepatic failure
MY153249A (en) 2005-11-14 2015-01-29 Rinat Neuroscience Corp Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
HUE034269T2 (en) * 2005-12-29 2018-02-28 Janssen Biotech Inc Human anti-il-23 antibodies, compositions, methods and uses
AU2006332713B2 (en) 2005-12-30 2013-01-17 Takeda Pharmaceutical Company Limited Metalloproteinase binding proteins
AR056857A1 (en) 2005-12-30 2007-10-24 U3 Pharma Ag DIRECTED ANTIBODIES TO HER-3 (RECEIVER OF THE HUMAN EPIDERMAL GROWTH FACTOR-3) AND ITS USES
US20090054763A1 (en) * 2006-01-19 2009-02-26 The Regents Of The University Of Michigan System and method for spectroscopic photoacoustic tomography
CL2007002668A1 (en) 2006-09-20 2008-05-09 Amgen Inc ANTIGEN UNION PROTEIN THAT JOINS THE HUMAN GLUCAGON RECEIVER; NUCLEIC ACID THAT CODIFIES IT; METHOD OF PRODUCTION; PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT; AND ITS USE TO TREAT OR PREVENT TYPE 2 DIABETES.
US20080123083A1 (en) * 2006-11-29 2008-05-29 The Regents Of The University Of Michigan System and Method for Photoacoustic Guided Diffuse Optical Imaging
US7884184B2 (en) * 2007-01-30 2011-02-08 Epivax, Inc. Regulatory T cell epitopes, compositions and uses thereof
US7807168B2 (en) * 2007-04-10 2010-10-05 Vaccinex, Inc. Selection of human TNFα specific antibodies
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
TW201531484A (en) 2007-05-21 2015-08-16 Alder Biopharmaceuticals Inc Antibodies to TNF alpha and use thereof
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US7935340B2 (en) 2007-05-21 2011-05-03 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
WO2008141511A1 (en) * 2007-05-22 2008-11-27 Human Antibodomics (Shanghai) Inc. A HUMAN ANTI-TNFα MONOCLONAL ANTIBODY AND THE USE THEREOF
WO2009018429A2 (en) * 2007-07-31 2009-02-05 The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Healt Of Human Services, National Institutes Of Healt TREATMENT OF CANCER VIA TARGETING OF IL-13 RECEPTOR-α2
EP2231186A4 (en) 2007-12-17 2012-08-08 Dyax Corp Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins
CN101970494B (en) 2008-02-20 2015-01-21 G2炎症私人有限公司 Humanized anti-c5ar antibodies
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
NZ587292A (en) 2008-03-04 2012-09-28 Pfizer Ltd Use of anti-CGRP (calcitonin gene-related peptide) antagonists to treat chronic pain
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US9109026B2 (en) 2008-06-03 2015-08-18 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
RU2010153580A (en) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND THEIR APPLICATION
MX2010014574A (en) 2008-07-08 2011-04-27 Abbott Lab Prostaglandin e2 dual variable domain immunoglobulins and uses thereof.
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9452227B2 (en) * 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
CN101896502B (en) * 2009-03-20 2012-10-17 刘庆法 A human anti-tumor necrosis factor alpha monoclonal antibody and use thereof
SG177689A1 (en) * 2009-07-31 2012-02-28 Organon Nv Fully human antibodies to btla
WO2011015919A1 (en) * 2009-08-03 2011-02-10 Avesthagen Limited A highly efficient process of purification and production of recombinant infliximab
ES2912569T3 (en) 2009-08-28 2022-05-26 Teva Pharmaceuticals Int Gmbh Methods of treating visceral pain by administering antagonistic antibodies directed against calcitonin gene-related peptide
UY32979A (en) * 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
CN105999263B (en) 2009-11-13 2021-06-29 第一三共欧洲有限公司 Materials and methods for treating or preventing human epidermal growth factor receptor-3 (HER-3) related diseases
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
WO2011066369A2 (en) 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antagonists of il-6 to raise albumin and/or lower crp
CN102167741B (en) * 2010-02-25 2014-05-14 上海百迈博制药有限公司 Fully human anti-TNF-alpha (Tumor Necrosis Factor-alpha) monoclonal antibody and preparation method as well as application thereof
NZ603045A (en) * 2010-04-07 2014-11-28 Abbvie Inc Tnf-alpha binding proteins
PE20131412A1 (en) 2010-08-03 2014-01-19 Abbvie Inc IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
TW201211252A (en) 2010-08-26 2012-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2810851C (en) 2010-09-09 2022-08-02 University Of Southern California Compositions and methods for the removal of biofilms comprising a high-mobility group-box (hmg-box) domain containing polypeptide
CN102443063B (en) * 2010-09-30 2013-10-23 成都康弘生物科技有限公司 Anti-TNFalpha humanized Fab, humanized antibody and its application
WO2012071554A2 (en) 2010-11-23 2012-05-31 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of oral mucositis
AR084210A1 (en) 2010-12-08 2013-05-02 Abbott Lab PROTEINS OF UNION TO TNF-a
US10654916B2 (en) 2011-04-21 2020-05-19 The Regents Of The University Of California, A California Corporation Compositions and methods for the treatment of neuromyelitis optica
US9745373B2 (en) 2011-05-20 2017-08-29 Alderbio Holdings Llc Anti-CGRP compositions and use thereof
JP6189832B2 (en) 2011-05-20 2017-08-30 アルダーバイオ・ホールディングズ・エルエルシー Use of anti-CGRP or anti-CGRP-R antibodies or antibody fragments to treat or prevent chronic and acute diarrhea
CN103702685B (en) 2011-05-20 2017-12-15 奥尔德生物控股有限责任公司 Anti- CGRP antibody and antibody fragment are used to prevent or suppress photophobia in subject in need, especially migraineur or detest the purposes of light
DK3424953T3 (en) * 2011-06-06 2020-11-02 Novo Nordisk As Terapeutiske antistoffer
JP2014523745A (en) * 2011-07-20 2014-09-18 メディミューン リミテッド Anti-CXCR4 antibody and method of use
US10314909B2 (en) 2011-10-21 2019-06-11 Dyax Corp. Combination therapy comprising an MMP-14 binding protein
KR20140084254A (en) 2011-10-24 2014-07-04 애브비 인코포레이티드 Bispecific immunobinders directed against tnf and il-17
AR088512A1 (en) 2011-10-24 2014-06-18 Abbvie Inc ANTIBODIES DIRECTED AGAINST TNF
TW201323440A (en) 2011-10-24 2013-06-16 Abbvie Inc Immunobinders directed against sclerostin
EP2794656B1 (en) 2011-12-21 2019-02-27 Novartis AG Compositions comprising antibodies targeting factor p and c5
US20130171059A1 (en) * 2011-12-30 2013-07-04 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
TW201333035A (en) 2011-12-30 2013-08-16 Abbvie Inc Dual specific binding proteins directed against IL-13 and/or IL-17
WO2013165972A2 (en) * 2012-04-30 2013-11-07 Cell Signaling Technology, Inc. Anti-hepatitis b virus antibodies and use thereof
WO2014028446A1 (en) 2012-08-13 2014-02-20 Genentech, Inc. Anti-jagged anitbodies and methods of use
KR20190107184A (en) 2012-11-01 2019-09-18 애브비 인코포레이티드 Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
UY35148A (en) 2012-11-21 2014-05-30 Amgen Inc HETERODIMERIC IMMUNOGLOBULINS
BR112015023797A2 (en) 2013-03-15 2017-10-24 Abbvie Inc dual specificity binding proteins directed against il-1b and / or il-17
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US9409139B2 (en) 2013-08-05 2016-08-09 Twist Bioscience Corporation De novo synthesized gene libraries
EP3041863A4 (en) 2013-09-05 2017-08-16 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
US10233234B2 (en) 2014-01-13 2019-03-19 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US20150086561A1 (en) * 2013-09-26 2015-03-26 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
EP3094973B1 (en) 2013-11-07 2020-07-29 Diagnodus Limited Biomarkers
JP6533534B2 (en) 2014-02-14 2019-06-19 マクロジェニクス，インコーポレーテッド Composition for use in the treatment of glioblastoma and use thereof
CN104892760B (en) * 2014-03-04 2018-04-17 北京安保康生物医药科技有限公司 The full human monoclonal antibody of anti-TNF alpha and its application
IL247853B (en) 2014-03-21 2022-08-01 Teva Pharmaceuticals Int Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MX2016014761A (en) 2014-05-16 2017-05-25 Amgen Inc Assay for detecting th1 and th2 cell populations.
GB201419094D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
US10259874B2 (en) 2014-10-27 2019-04-16 Agency For Science, Technology And Research Anti-TIM-3 antibodies
WO2016073853A1 (en) * 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
CA2975852A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
AU2016219170B2 (en) 2015-02-13 2021-09-09 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CTLA4
US10100118B2 (en) * 2015-04-08 2018-10-16 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD123
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
ES2962885T3 (en) * 2015-05-15 2024-03-21 Massachusetts Gen Hospital Tumor necrosis factor receptor superfamily antagonist antibodies
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
US10940204B2 (en) 2015-07-31 2021-03-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
EP3922645A1 (en) 2015-09-15 2021-12-15 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
AU2016324296A1 (en) 2015-09-18 2018-04-12 Twist Bioscience Corporation Oligonucleic acid variant libraries and synthesis thereof
US11512347B2 (en) 2015-09-22 2022-11-29 Twist Bioscience Corporation Flexible substrates for nucleic acid synthesis
CR20180365A (en) 2015-12-16 2018-09-28 Amgen Inc PROTEINS OF UNION TO THE ANTI-TL1A / ANTI-TNF-a BISPECTIVE ANTIGEN AND ITS USES
US10287345B2 (en) 2016-01-08 2019-05-14 Scholar Rock, Inc. Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies
EP3400013A4 (en) * 2016-01-09 2019-09-11 Arbele Limited Cadherin-17 specific antibodies and cytotoxic cells for cancer treatment
CA3016870A1 (en) * 2016-03-17 2017-09-21 Numab Innovation Ag Anti-tnf.alpha.-antibodies and functional fragments thereof
KR20230169484A (en) 2016-06-13 2023-12-15 스칼러 락, 인크. Use of myostatin inhibitors and combination therapies
JP2019526623A (en) * 2016-08-08 2019-09-19 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Anti-OX40 binding protein
WO2018057526A2 (en) 2016-09-21 2018-03-29 Twist Bioscience Corporation Nucleic acid based data storage
CN109952314A (en) 2016-09-23 2019-06-28 泰瓦制药国际有限公司 Treat intractable migraine
AR110414A1 (en) * 2016-12-21 2019-03-27 Cephalon Inc ANTIBODIES THAT SPECIFICALLY JOIN HUMAN IL-15 AND USES OF THESE
US11564982B2 (en) 2017-01-04 2023-01-31 Research Institute At Nationwide Children's Hospital DNABII vaccines and antibodies with enhanced activity
US11155611B2 (en) 2017-01-06 2021-10-26 Scholar Rock, Inc. Compositions and methods for making and using anti-myostatin antibodies
CN110892485B (en) 2017-02-22 2024-03-22 特韦斯特生物科学公司 Nucleic acid-based data storage
SG11201908328XA (en) 2017-03-14 2019-10-30 Amgen Inc Control of total afucosylated glycoforms of antibodies produced in cell culture
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
US10696965B2 (en) 2017-06-12 2020-06-30 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
US11649286B2 (en) * 2017-06-25 2023-05-16 Systimmune Inc. Tri-specific antibodies
EP3681906A4 (en) 2017-09-11 2021-06-09 Twist Bioscience Corporation Gpcr binding proteins and synthesis thereof
GB2583590A (en) 2017-10-20 2020-11-04 Twist Bioscience Corp Heated nanowells for polynucleotide synthesis
US11142579B2 (en) 2017-12-06 2021-10-12 Sorrento Therapeutics, Inc. Variant antibodies that bind OX40
CA3093853A1 (en) 2018-03-26 2019-10-03 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
SG11202011467RA (en) 2018-05-18 2020-12-30 Twist Bioscience Corp Polynucleotides, reagents, and methods for nucleic acid hybridization
CA3120237A1 (en) 2018-11-20 2020-05-28 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il-23 specific antibody
US11639380B2 (en) 2019-01-08 2023-05-02 H. Lundbeck A/S Acute treatment and rapid treatment of headache using anti-CGRP antibodies
WO2020176680A1 (en) 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for antibody optimization
AU2020251028A1 (en) * 2019-04-04 2021-10-28 Janssen Biotech, Inc. Anti-HLA-C antibodies and uses thereof
CN113874073A (en) 2019-05-23 2021-12-31 詹森生物科技公司 Methods of treating inflammatory bowel disease with combination therapy of antibodies to IL-23 and TNF α
CA3144644A1 (en) 2019-06-21 2020-12-24 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
JPWO2021015237A1 (en) * 2019-07-24 2021-01-28
AU2020356471A1 (en) * 2019-09-23 2022-04-21 Twist Bioscience Corporation Variant nucleic acid libraries for CRTH2
US20220349898A1 (en) 2019-09-26 2022-11-03 Amgen Inc. Methods of producing antibody compositions
CN111153994B (en) * 2019-12-31 2021-10-15 武汉班科生物技术股份有限公司 Human monoclonal antibodies to human tumor necrosis factor
WO2021154530A1 (en) * 2020-01-27 2021-08-05 Vanderbilt University Human anti-dengue antibodies and methods of use therefor
WO2021222128A1 (en) * 2020-04-27 2021-11-04 Fred Hutchinson Cancer Research Center Neutralizing monoclonal antibodies against covid-19
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
KR20220012826A (en) * 2020-07-23 2022-02-04 (주)셀트리온 SARS-CoV-2 NEUTRALIZING BINDING MOLECULE BINDING TO EPITOPES OF SARS-CoV-2 SPIKE PROTEIN
CA3190667A1 (en) * 2020-08-26 2022-03-03 Aaron Sato Methods and compositions relating to glp1r variants
US20240043501A1 (en) 2020-10-15 2024-02-08 Amgen Inc. Relative unpaired glycans in antibody production methods
JP2023554200A (en) 2020-12-09 2023-12-26 エイチケー イノ．エヌ コーポレーション Anti-OX40L antibody, anti-OX40L and anti-TNFα bispecific antibody, and their uses
TW202317614A (en) 2021-06-07 2023-05-01 美商安進公司 Using fucosidase to control afucosylation level of glycosylated proteins
CA3233279A1 (en) 2021-10-05 2023-04-13 Amgen, Inc. Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
CN115819565A (en) * 2022-06-06 2023-03-21 百斯医学诊断科技(北京)有限公司 Novel coronavirus Omicron mutant strain specific antibody and application thereof

Family Cites Families (239)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4309418A (en) 1980-03-25 1982-01-05 Sloan-Kettering Research Institute For Cancer Anti-tumor agent from human serum and process
ATE12348T1 (en) 1980-11-10 1985-04-15 Gersonde Klaus Prof Dr PROCESS FOR THE PRODUCTION OF LIPID VESICLES BY ULTRASONIC TREATMENT, APPLICATION OF THE PROCESS AND DEVICE FOR CARRYING OUT THE PROCESS.
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
SE8204382L (en) 1981-07-21 1983-01-22 Hayashibara Biochem Lab PUT TO MAKE MALCELLY FACTOR AND USE THEREOF
US4603106A (en) 1982-02-22 1986-07-29 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US6309640B1 (en) 1981-09-08 2001-10-30 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US6419927B1 (en) 1981-09-08 2002-07-16 Anthony Cerami Method for reducing adverse effects of a human 70kDa mediator which results from endotoxin stimulation of macrophages
US4822776A (en) 1981-09-08 1989-04-18 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US5700466A (en) 1981-09-08 1997-12-23 The Rockefeller University Method of ameliorating or preventing septic shock using a monoclonal antibody specific to cachectin/tumor necrosis factor
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
JPS58118008A (en) 1982-01-06 1983-07-13 Nec Corp Data processor
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
JPS58166633A (en) 1982-03-29 1983-10-01 Toshiba Corp Positive electrode for organic solvent cell
JPS58166634A (en) 1982-03-29 1983-10-01 Toshiba Corp Positive electrode for organic solvent cell
HU189251B (en) 1982-04-07 1986-06-30 Asahi Kasei Kogyo Kk,Jp Process for stabilizing tumor necrosis factor
DE3218121A1 (en) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Pharmaceutical compositions for tumour treatment
EP0102324A3 (en) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipids and surfactants in an aqueous medium
US4390468A (en) 1982-08-04 1983-06-28 Maruzen Oil Co., Ltd. Preparation of antitumor agent from shellfish
US4457916A (en) 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS6019719A (en) 1983-07-15 1985-01-31 Asahi Chem Ind Co Ltd Protein having antitumor activity
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4678773A (en) 1983-08-26 1987-07-07 Chugai Seiyaku Kabushiki Kaisha Antitumor agent
EP0350973B1 (en) 1983-09-26 1997-11-05 Udo Dr. Ehrenfeld Means and product for the diagnosis and therapy of tumours and for the treatment of weaknesses of the cellular and humoral immune system
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
JPS60112718A (en) 1983-11-21 1985-06-19 Kyorin Pharmaceut Co Ltd Proteinous substance exhibiting antitumor activity and its production
JPH0695939B2 (en) 1983-12-02 1994-11-30 大日本製薬株式会社 Cloned DNA coding for rabbit cancer necrosis factor
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5288852A (en) 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
US4894334A (en) 1984-03-28 1990-01-16 Cetus Corporation Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria
US4656132A (en) 1984-03-28 1987-04-07 Cetus Corporation Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria
US4879226A (en) 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
DE3423234A1 (en) 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim SYNERGISTIC MIXTURES OF INTERFERON AND TUMOR-NECROSE FACTOR
US4650674A (en) 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
WO1986002068A1 (en) 1984-09-26 1986-04-10 Takeda Chemical Industries, Ltd. Mutual separation of proteins
US4677064A (en) 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
JPS61124392A (en) 1984-11-22 1986-06-12 Asahi Chem Ind Co Ltd Purification of physiologically active substance produced by gene recombinant
IL73883A (en) 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
EP0313104A3 (en) 1984-12-21 1989-07-12 Biogen, Inc. Purification, production and use of tumor necrosis factors
US4900724A (en) 1985-03-04 1990-02-13 Sawai Pharmaceutical Co., Ltd Tumor necrosis factor inducing substance derived from acid-fast bacteria
US4684623A (en) 1985-05-02 1987-08-04 The Board Of Trustees Of The Cetus Corporation Use of tumor necrosis factor as a weight regulator
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
DE3526096A1 (en) 1985-07-22 1987-01-22 Basf Ag METHOD FOR PURIFYING HTNF
US4770995A (en) 1985-08-29 1988-09-13 New York Blood Center, Inc Detection of the sensitivity of cells to the effects of tumor necrosis factor and lymphotoxin
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
JPH0698004B2 (en) 1985-09-30 1994-12-07 サントリー株式会社 Novel plasmid for TNF expression
US5059530A (en) 1985-09-30 1991-10-22 Suntory Ltd. Expression vector for human TNF
US5182196A (en) 1985-10-09 1993-01-26 Biogen, Inc. Expression systems for overproduction of desired proteins
US4677197A (en) 1985-10-30 1987-06-30 Cetus Corporation Purification method for tumor necrosis factor
US4894439A (en) 1986-05-22 1990-01-16 Cetus Corporation N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes
JPS62170639A (en) 1986-01-22 1987-07-27 株式会社システムメンテナンス Method for mounting ant-proof panel
DE3750915T2 (en) 1986-02-04 1995-08-24 Den Ichi Mizuno DNA encoding antitumor polypeptides, the polypeptides and antitumor agents containing these polypeptides.
US4822605A (en) 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
US5425940A (en) 1986-04-09 1995-06-20 Cetus Oncology Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US4863727A (en) 1986-04-09 1989-09-05 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
CA1310924C (en) 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
ATE107362T1 (en) 1986-06-20 1994-07-15 Dainippon Pharmaceutical Co HUMAN TNF POLYPEPTIDE MUTANTS AND DNA ENCODING THESE MUTANTS.
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5866136A (en) * 1986-08-01 1999-02-02 Commonwealth Scientific And Industrial Organisation Recombinant vaccine
DE3631229A1 (en) 1986-09-13 1988-03-24 Basf Ag MONOCLONAL ANTIBODIES AGAINST HUMAN TUMORNESCROSE FACTOR (TNF) AND THEIR USE
US5002876A (en) 1986-09-22 1991-03-26 Phillips Petroleum Company Yeast production of human tumor necrosis factor
US4777242A (en) 1986-10-10 1988-10-11 Phillips Petroleum Company Purification of recombinant tumor necrosis factor
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
JPH07106158B2 (en) 1986-12-04 1995-11-15 サントリー株式会社 Novel polypeptide having antitumor activity and method for producing the same
US4894225A (en) 1987-03-02 1990-01-16 Cetus Corporation Combination therapy using antitumor immunotoxins with tumor necrosis factor
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
CA1340953C (en) 1987-04-08 2000-04-11 David W. Barnes Non-tumorigenic cell lines for expression of genes
JP2647427B2 (en) 1987-04-24 1997-08-27 帝人株式会社 Detection method, monoclonal antibody, and detection kit for determining disease state of subject
DE3716513A1 (en) 1987-05-16 1988-11-24 Basf Ag PROTEINS WITH TNF EFFECT
US6410033B1 (en) * 1987-07-27 2002-06-25 Syntro Corporation Recombinant infectious bovine rhinotracheitis virus
IL87737A (en) * 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
US5158871A (en) 1988-02-12 1992-10-27 University Of Connecticut Method of using magnetic particles for isolating, collecting and assaying diagnostic ligates
US5183657A (en) 1988-03-11 1993-02-02 Celltech Limited Antibodies for use in antilymphocyte antibody therapy
US5215743A (en) 1988-04-13 1993-06-01 Maninder Singh Tumor necrosis factor formulations
US5424940A (en) * 1988-04-25 1995-06-13 Ousborne; Jeffrey J. Computer controlled system providing functions within a laundromat facility
JPH0797997B2 (en) 1988-04-28 1995-10-25 帝人株式会社 Novel bioactive polypeptide
DE3823804A1 (en) 1988-07-14 1990-01-18 Basf Ag NEUTRALIZATION OF THE TOXIC PROPERTIES OF TNF- (ALPHA) IN VITRO AND VIVO BY MONOCLONAL ANTIBODIES AND THE FRAGMENTS DERIVED FROM THEM
AU626572B2 (en) 1988-07-18 1992-08-06 Chiron Corporation Monoclonal antibodies reactive with cachectin
DE68926679T2 (en) 1988-09-22 1996-10-17 Teijin Ltd PHYSIOLOGICALLY ACTIVE POLYPEPTIDE, RECOMBINANT PLASMIDE, RECOMBINANT MICROBIAL CELLS, MEDICAL PREPARATION AND METHOD FOR OBTAINING THE PURIFIED POLYPEPTIDE
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5360716A (en) 1988-10-24 1994-11-01 Otsuka Pharmaceutical Co., Ltd. Human tumor necrosis factor αspecific monoclonal antibody and method for detecting human tumor necrosis factor α
US5510418A (en) 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
US5162430A (en) 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5223395A (en) 1988-12-01 1993-06-29 Centocor, Inc. Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
ES2238070T3 (en) 1989-04-21 2005-08-16 Amgen Inc. TNF RECEPTOR, TNF BINDING PROTEIN AND CODANT DNA FOR THESE.
US6262239B1 (en) 1989-05-18 2001-07-17 Yeda Research And Development Co., Ltd. TNF receptor-specific antibodies
US6232446B1 (en) * 1989-05-18 2001-05-15 Yeda Research And Development Co. Ltd. TNF ligands
US6448380B2 (en) 1989-08-07 2002-09-10 Peptech Limited Tumor necrosis factor antibodies
US5959087A (en) 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
US5644034A (en) 1989-08-07 1997-07-01 Peptide Technology Ltd. Tumour necrosis factor binding ligands
ES2125854T3 (en) 1989-08-09 1999-03-16 Rhomed Inc DIRECT RADIO LABELING OF ANTIBODIES AND OTHER PROTEINS WITH TECNETIO OR RENIUM.
US6315999B1 (en) 1989-08-10 2001-11-13 Solvay, S.A. Pharmaceutical product for the treatment of sepsis
EP0487610B1 (en) 1989-08-16 2000-02-09 Chiron Corporation Prohormone cleavage site blocking antibody
US6541610B1 (en) * 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
ATE199398T1 (en) * 1989-10-24 2001-03-15 Chiron Corp SECRETION OF HUMAN PROTEIN BONDED WITH GAMMA INTERFERON SIGNAL PEPTIDE
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP3068180B2 (en) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド Generation of heterologous antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5672510A (en) 1990-01-19 1997-09-30 Genetic Therapy, Inc. Retroviral vectors
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5110913A (en) 1990-05-25 1992-05-05 Miles Inc. Antibody purification method
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
JPH06500323A (en) 1990-08-27 1994-01-13 ペプチド　テクノロジィ　リミテッド How to treat viral infections
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (en) 1990-08-29 1997-09-15 Genpharm Int PRODUCTION AND USE OF NON-HUMAN TRANSGENT ANIMALS FOR THE PRODUCTION OF HETEROLOGUE ANTIBODIES
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
JPH06506105A (en) 1990-08-29 1994-07-14 ファーミング　ビーブイ Homologous recombination in mammalian cells
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
US5519119A (en) 1990-09-21 1996-05-21 Ishihara Sangyo Kaisha Ltd. Muteins of TNF pharmaceutical compositions and a method of making
JPH05255393A (en) 1990-09-21 1993-10-05 Ishihara Sangyo Kaisha Ltd Polypeptide
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
US5653974A (en) 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
CA2055168A1 (en) 1990-11-21 1992-05-22 Walter Fiers Tnf-muteins
ATE164395T1 (en) 1990-12-03 1998-04-15 Genentech Inc METHOD FOR ENRICHMENT OF PROTEIN VARIANTS WITH MODIFIED BINDING PROPERTIES
US5994510A (en) 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
GB9028123D0 (en) 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
US5698195A (en) 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
ES2289997T3 (en) 1991-03-18 2008-02-16 New York University SPECIFIC MONOCLONAL AND CHEMICAL ANTIBODIES FOR THE HUMAN TUMOR NECROSIS FACTOR.
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5160483A (en) 1991-05-07 1992-11-03 The University Of Tennessee Research Corporation Fragment of TNF-α for promoting wound healing
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
FR2677654B1 (en) 1991-06-17 1995-11-17 Pasteur Merieux Serums Vacc COMPOUNDS WITH AN IMMUNOGENIC ANTI-CYTOKIN EFFECT, AN ANTIYTOSTATIC IMMUNOGENIC EFFECT OR AN ANTI-HIV INFECTION VACCINE EFFECT.
US5633146A (en) 1991-07-02 1997-05-27 Rhone-Poulenc Rorer S.A. Method for producing recombinant proteins and host cells used therein
US5223408A (en) 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
US5965379A (en) 1991-07-19 1999-10-12 Cytimmune Sciences Inc. Method for measuring endogenous cytokines
MX9204374A (en) 1991-07-25 1993-03-01 Idec Pharma Corp RECOMBINANT ANTIBODY AND METHOD FOR ITS PRODUCTION.
FR2679920A1 (en) 1991-08-02 1993-02-05 Rhone Poulenc Rorer Sa Highly stable recombinant yeasts for the production of recombinant proteins, their preparation and their use
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5334380A (en) 1991-09-27 1994-08-02 Board Of Regents, The University Of Texas System Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US6261834B1 (en) 1991-11-08 2001-07-17 Research Corporation Technologies, Inc. Vector for gene therapy
US5885793A (en) * 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
SK376492A3 (en) 1992-04-02 1995-06-07 Hoffmann La Roche Tnf - muteins and method of their production
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5278284A (en) 1992-05-14 1994-01-11 Miller Brewing Company Protein purification method
EP0648265A4 (en) 1992-06-18 1996-12-04 Genpharm Int Methods for producing transgenic non-human animals harboring a yeast artificial chromosome.
ES2301158T3 (en) 1992-07-24 2008-06-16 Amgen Fremont Inc. XENOGENIC ANTIBODY PRODUCTION.
EP0585705B1 (en) 1992-08-28 1998-11-04 Bayer Corporation Use of monoclonal antibodies to TNF to treat bacterial meningitis
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
EP0663836B1 (en) * 1992-10-08 1997-07-09 The Kennedy Institute Of Rheumatology Treatment of autoimmune and inflammatory disorders
JPH08509203A (en) * 1992-10-15 1996-10-01 ダナ−ファーバー キャンサー インステテュート インコーポレイテッド Treatment of obesity-related diabetes type II insulin resistance with antagonists of TNF-α action
US5968735A (en) 1992-11-12 1999-10-19 Max Delbruck-Centrum Fur Molekular Medizin Berlin Vector for the expression of therapy-relevant genes
AU690528B2 (en) 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
GB9225448D0 (en) * 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
US5981175A (en) 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
EP0682705A1 (en) * 1993-02-03 1995-11-22 N.V. Innogenetics S.A. Tnf-alpha muteins and a process for preparing them
KR970005042B1 (en) * 1993-02-09 1997-04-11 한일합성섬유공업 주식회사 Tumor necrosis factor-alpha muteine
US5626843A (en) 1993-02-26 1997-05-06 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS, by removel of interferons, TNFs and receptors therefor
EP0614984B2 (en) 1993-03-05 2010-11-03 Bayer HealthCare LLC Anti-TNF alpha human monoclonal antibodies
CA2119089A1 (en) 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1994029347A1 (en) * 1993-06-03 1994-12-22 Therapeutic Antibodies Inc. Antibody fragments in therapy
WO1995003827A1 (en) 1993-07-30 1995-02-09 Kennedy Institute Of Rheumatology Method for treating multiple sclerosis
FR2709309B1 (en) * 1993-08-25 1995-11-10 Centre Nat Rech Scient Cellular compositions, preparation and therapeutic uses.
US6268212B1 (en) 1993-10-18 2001-07-31 Amgen Inc. Tissue specific transgene expression
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5959085A (en) 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
NZ278607A (en) * 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
WO1995025809A1 (en) * 1994-03-23 1995-09-28 Ohio University Compacted nucleic acids and their delivery to cells
ATE207967T1 (en) * 1994-05-17 2001-11-15 Cedars Sinai Medical Center METHOD FOR SCREENING FOR CROHN'S DISEASE BY USING TNF MICROSATELLITE ALLELES
US5606023A (en) 1994-05-24 1997-02-25 Thomas Jefferson University Mutant tumor necrosis factor proteins
US5888814A (en) * 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
US5989808A (en) 1994-06-14 1999-11-23 American Cyanamid Company Identification of compounds affecting specific interaction of peptide binding pairs
DE4435612A1 (en) 1994-10-05 1996-04-11 Braun Melsungen Ag Process for the simultaneous removal of tumor necrosis factor alpha and bacterial lipopolysaccharides from an aqueous liquid
US5763733A (en) * 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US5753499A (en) * 1994-12-23 1998-05-19 New York University Viral vector complexes having adapters of predefined valence
US6127528A (en) 1995-02-16 2000-10-03 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Process for adsorbing and removing tumor necrosis factor-α
PT814778E (en) * 1995-03-10 2001-11-30 Roche Diagnostics Gmbh METHODS OF PHARMACEUTICAL ADMINISTRATION CONTAINING POLYPREPEPTIDES IN THE FORM OF MICROPARTICLES AND PROCESS FOR THEIR PREPARATION
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
EP0843961B1 (en) 1995-08-29 2007-01-24 Kirin Beer Kabushiki Kaisha Chimeric animal and method for constructing the same
US6022737A (en) * 1995-11-02 2000-02-08 Amgen Inc. Formulations for non-viral in vivo transfection in the lungs
FR2741262B1 (en) * 1995-11-20 1999-03-05 Oreal USE OF A TNF-ALPHA ANTAGONIST FOR THE TREATMENT OF CUTANEOUS REDNESS OF NEUROGENIC ORIGIN
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5789442A (en) * 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
HU228630B1 (en) * 1996-02-09 2013-04-29 Abbott Biotech Ltd Use of human anti bodies that bind human tnf-alpha and process for inhibiting of human tnf-alpha activity
EP0792083B1 (en) * 1996-02-23 1999-07-28 Samsung Electronics Co., Ltd. A method for controlling a microwave oven to prevent overcooking of small food portions
EP0791360A3 (en) 1996-02-29 1997-09-24 Bayer Corporation Treatment of septic shock with anti-TNF antibodies
US5952221A (en) * 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence
ATE403001T1 (en) * 1996-05-22 2008-08-15 Viventia Biotech Inc ANTIGEN BINDING FRAGMENTS SPECIFICALLY DETECTING CANCER CELLS, NUCLEOTIDES ENCODING THESE FRAGMENTS, AND THEIR USE IN PREVENTING AND DETECTING CANCER
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
KR20080059467A (en) * 1996-12-03 2008-06-27 아브게닉스, 인크. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
WO1998029336A1 (en) * 1996-12-31 1998-07-09 Chevron U.S.A. Inc. Zeolite ssz-48
US5917123A (en) * 1997-03-14 1999-06-29 University Of Pittsburgh Transgenic mice containing a nucleic acid encoding tumor necrosis factor-α under the control of a cardiac specific regulatory region
US6099847A (en) 1997-05-15 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric Gag pseudovirions
US6210976B1 (en) * 1997-06-10 2001-04-03 Medlyte Diagnostics, Inc. Methods for early detection of heart disease
GB9713412D0 (en) * 1997-06-26 1997-08-27 Delta Biotechnology Ltd Improved protein expression strains
US6407218B1 (en) * 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
CA2314246A1 (en) * 1997-12-11 1999-07-29 Pangene Corporation The use of consensus sequences for targeted homologous gene isolation and recombination in gene families
CA2317839A1 (en) 1998-01-22 1999-07-29 Btg International Limited Inhibition of cytokine production
BR9912070A (en) * 1998-07-13 2001-04-10 Expression Genetics Inc Poly-l-lysine polyester analog as a soluble, biodegradable gene delivery vehicle
US6136599A (en) 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
US6015557A (en) * 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
CA2376108A1 (en) * 1999-06-03 2000-12-14 Maxim Pharmaceuticals, Inc. Ophthalmic histamine compositions and uses thereof
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
DK1223915T3 (en) * 1999-10-29 2006-03-06 Nektar Therapeutics Dry powder preparations with improved dispersivity
US6524572B1 (en) * 2000-06-26 2003-02-25 Rainbow Therapeutic Company Targeting recombinant virus with a bispecific fusion protein ligand in coupling with an antibody to cells for gene therapy
CA2478547C (en) 2001-12-03 2011-09-20 Abgenix, Inc. Identification of high affinity molecules by limited dilution screening
EP1578799B8 (en) * 2002-12-02 2011-03-23 Amgen Fremont Inc. Antibodies directed to tumor necrosis factor and uses thereof
US11284893B2 (en) 2019-04-02 2022-03-29 Covidien Lp Stapling device with articulating tool assembly

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8221752B2 (en) 2004-06-09 2012-07-17 Wyeth Llc Antibodies against human interleukin-13 and uses therefor
US7943342B2 (en) 2004-06-17 2011-05-17 Wyeth Llc Nucleic acids encoding IL-13 binding agents

Also Published As

Publication number Publication date
EP1578799B8 (en) 2011-03-23
US20080187531A1 (en) 2008-08-07
ATE472556T1 (en) 2010-07-15
RU2377253C2 (en) 2009-12-27
WO2004050683A2 (en) 2004-06-17
WO2004050683A3 (en) 2005-04-14
AU2003298816C1 (en) 2010-12-16
CN1745101A (en) 2006-03-08
CA2508375A1 (en) 2004-06-17
CN100434440C (en) 2008-11-19
HK1083023A1 (en) 2006-06-23
EP1578799A2 (en) 2005-09-28
RU2005116225A (en) 2006-02-27
MXPA05005921A (en) 2005-10-19
DE60333228D1 (en) 2010-08-12
EP1578799A4 (en) 2007-04-04
US20050049402A1 (en) 2005-03-03
JP2006508167A (en) 2006-03-09
AU2003298816B2 (en) 2010-06-17
US7285269B2 (en) 2007-10-23
JP4754219B2 (en) 2011-08-24
ES2347239T3 (en) 2010-10-27
US8101178B2 (en) 2012-01-24
CA2508375C (en) 2014-05-27
EP1578799B1 (en) 2010-06-30
AU2003298816A1 (en) 2004-06-23

Similar Documents

Publication Publication Date Title
WO2004050683A8 (en) Antibodies directed to tumor necrosis factor and uses thereof
WO2003057857A3 (en) Antibodies directed to pdgfd and uses thereof
WO2006130458A3 (en) Antibodies directed to cd20 and uses thereof
TW200634027A (en) Antibodies directed to angiopoietin-2 and uses thereof
WO2006081139A3 (en) Antibodies against interleukin-1 beta
WO2005118635A3 (en) Anti-cd3 antibodies and methods of use thereof
WO2007120693A3 (en) Targeted binding agents directed to upar and uses thereof
WO2004050850A3 (en) Antibodies directed to phospholipase a2 and uses thereof
WO2008112004A3 (en) ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF
WO2004084823A3 (en) Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
WO2004016769A3 (en) Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
WO2006104978A3 (en) Antibodies against the tenascin major antigens
WO2006052591A3 (en) Anti-properdin antibodies, and methods for making and using same
WO2007109307A3 (en) Antibodies directed to angiopoietin-like protein 4 and uses thereof
WO1998050433A3 (en) Human monoclonal antibodies to epidermal growth factor receptor
WO2007070432A3 (en) Binding proteins specific for insulin-like growth factors and uses thereof
WO2005016111A3 (en) Antibodies directed to parathyroid hormone (PTH) and uses thereof
WO2000037504A3 (en) Human monoclonal antibodies to ctla-4
WO2006039258A3 (en) Human antibodies against parathyroid hormone
WO2006055638A3 (en) Fully human monoclonal antibodies to il-13
EP2548583A3 (en) Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
WO2006055704A3 (en) Antibodies directed to ten-m proteins and uses thereof
WO2004050032A3 (en) Antibodies against drugs of abuse
WO2007065037A3 (en) Antibodies against mmp-13 (collagenase-3) and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003298816

Country of ref document: AU

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003796574

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2508375

Country of ref document: CA

Ref document number: 2004557489

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/005921

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2005116225

Country of ref document: RU

Kind code of ref document: A

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 25/2004 UNDER (72, 75) REPLACE "QIAOJUAN, JANE, SU" BY "SU, QIAOJUAN, JANE"

WWE Wipo information: entry into national phase

Ref document number: 20038A94561

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003796574

Country of ref document: EP